Anidulafungin: an echinocandin antifungal

Bibliography

• Anidulafungin: ECB, LY 303366, V-echinocandin, VEC, VER 002, VER-02. Drugs R&D (2003) 4:167–173.
   PubMedGoogle Scholar
• MARTIN-MAZUELOS E: Anidulafungin. IDrugs (2003) 6:980–986.
   PubMed Web of Science ®Google Scholar
• KRISHNARAO TV, GALGIANI JN: Comparison of the in vitro activities of the echinocandin LY303366, the pneumocandin MK-0991, and fluconazole against Candida species and Cryptococcus neoformans. Antimicrob. Agents Chemother. (1997) 41:1957–1960.
   PubMed Web of Science ®Google Scholar
• ZHANEL GG, KARLOWSKY JA, HARDING GA et al: In vitro activity of a new semisynthetic echinocandin, LY303366, against systemic isolates of Candida species, Cryptococcus neoformans, Blastomyces dermatitidis, and Aspergillus species. Antimicrob. Agents Chemother. (1997) 41:863–865.
   PubMed Web of Science ®Google Scholar
• GEORGOPAPADAKOU NH: Update on antifungals targeted to the cell wall: focus on 13-1, 3-glucan synthase inhibitors. Expert Opin. Investig. Drugs (2001) 10:269–280.
   PubMed Web of Science ®Google Scholar
• •Good review of cell-wall active antifungals.
   Google Scholar
• KURTZ MB, DOUGLAS CM: inhibitors of fungal glucan synthase. Med. Vet. Mycol. (1997) 35:79–86.
   PubMedGoogle Scholar
• JOHNSON MD, PERFECT JR: Caspofungin: first approved agent in a new class of antifungals. Expert Opin. Pharmacother. (2003) 4:807–823.
   PubMed Web of Science ®Google Scholar
• ARATHOON EG: Clinical efficacy of echinocandin antifungals. Can: Opin. Infect. Dis. (2001) 14:685–691.
   PubMed Web of Science ®Google Scholar
• ••A comprehensive review of allechinocandins, including anidulafungin, includes in vitro activity and in vivo studies as well as tolerability and pharmacokinetic data.
   Google Scholar
• STOGNIEW M, PU F, HENKEL T, DOWELL J: Anidulafungin biotransformation in humans is by degradation not metabolism. Clin. Microbial. Infect. (2003) 9:91.
   Google Scholar
• DOWELL JA, KNEBEL W, LUDDEN T, STOGNIEW M, KRAUSE D, T: Population pharmacokinetic analysis of anidulafungin, an echinocandin antifungal. .1 Clin. Pharm. (2004) 44:590–598.
   Google Scholar
• THYE D, KILFOIL G, HENKEL T: Anidulafungin: Safety and pharmacokinetics in subjects receiving concomitant cyclosporine. Abstracts of the 41st Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago, USA (2001) Abstract A1836.
   Google Scholar
• GRAYBILL JR: The echinocandins, first novel class of antifungals in two decades: Will they live up their promise? Int. j Clin. Pract. (2001) 55:633–638.
   Google Scholar
• DOUGLAS CM, D'IPPOLITO JA, SHEI GJ et al.: Identification of the FKS1 gene of Candida albicans as the essential target of 1, 3–3-D-glucan synthase inhibitors: Antimicrob. Agents Chemother. (1997) 41:2471–2479.
   Google Scholar
• DEBONO M, GORDEE RS: Antibiotics that inhibit fungal cell wall development. Ann. Rev Microbial. (1994) 48:471–497.
   PubMed Web of Science ®Google Scholar
• HECTOR RF: Compounds active against cell walls of medically important fungi. Clin. Microbial. Rev (1993) 6:1–21.
   PubMed Web of Science ®Google Scholar
• AREVALO MP,-MUNOZ A-J, SALGADO J et al.: Antifungal activity of the echinocandin anidulafungin (VER002, LY-303366) against yeast pathogens: a comparative study with M27-A microdilution method. I. Antimicrob. Chemother. (2003) 51:163–166.
   Google Scholar
• ESPINEL-INGROFF A: Comparison of in vitro activities of the new triazole 5CH56592 and the echinocandins-0991 (L-743, 872) and LY303366 against opportunistic filamentous and dimorphic fungi and yeasts. I. Clin. Microbial. (1998) 36:2950–2956.
   PubMed Web of Science ®Google Scholar
• •A useful in vitro comparison of anidulafungin and caspofungin against a broad range of fungi.
   Google Scholar
• MARCO F, PFALLER MA, MESSER SA, JONES RN: Activity of MK-0991 (L-743,872), a new echinocandin, compared with those of LY303366 and four other antifungal agents tested against blood stream isolates of Candida spp. Diagn. Microbial. Infect. Dis. (1998) 31:33–37.
   Web of Science ®Google Scholar
• UZUN 0, KOCAGOZ S, Y, ARIKAN S, UNAL S: In vitro activity of a new echinocandin, LY-303366, compared with those of amphotericin B and fluconazole against clinical yeast isolates. Antimicrob. Agents Chemother. (1997) 41:1156–1157.
   PubMed Web of Science ®Google Scholar
• PFALLER MA, MARCO F, MESSER SA, JONES RN: In vitro activity of two echinocandin derivatives, LY303366 and MK-0991 (L-743, 792), against clinical isolates of Aspergillus, Fusarium, Rhizopus, and other filamentous fungi. Diagn. Microbial. Infect. Dis. (1998) 30:251–255.
   PubMed Web of Science ®Google Scholar
• VERWEIJ PE, OAKLEY KL, MORRISSEY J, MORRISSEY G, DENNING DW: Efficacy of LY303366 against amphotericin B-susceptible and -resistant Aspergillus fumigatusin a murine model of invasive aspergillosis. Antimicrob. Agents Chemother. (1998) 42:873–878.
   PubMed Web of Science ®Google Scholar
• ODABASI Z, PAETZNICK VL, RODRIQUEZ JR, CHEN E, OSTROSKY-ZEICHNER L: In vitro activity of anidulafungin against selected clinically important mold isolates. Antimicrob. Agents Chemother. (2004) 48:1912–1915.
   PubMed Web of Science ®Google Scholar
• BARTLETT MS, CURRENT WL, GOHEEN MP et al.: Semisynthetic echinocandins affect cell wall deposition of Pneumocystis carinii in vitro and in vivo. Agents Chemother. (1996) 40:1811–1816.
   PubMed Web of Science ®Google Scholar
• CURRENT WL, BOYLAN CJ, RAAB PP:Antipneumocystis activity of LY303366 and other echinocandin B analogues. Abstracts of the 33rd Interscience Conference on Antimicrobial Agents and Chemotherapy New Orleans, USA (1993) Abstract 368.
   Google Scholar
• FELDMESSER M, KRESS Y, MEDNICK A, CASADEVALL A: The effects of the echinocandin analogue caspofungin on cell wall glucan synthesis by Cryptococcus neoformans. .1. Infect. Dis. (2000) 182:1791–1795.
   PubMed Web of Science ®Google Scholar
• KURTZ MB, ABRUZZO G, A et al: Characterization of echinocandin-resistant mutants of Candida albicans: genetic, biochemical, and virulence studies. Infect. Inman. (1996) 64:3244–3251.
   PubMed Web of Science ®Google Scholar
• OSHEROV N, MAY GS, ALBERT ND, KONTOYIANNIS DP: Overexpression of Sbe2p, a Golgi protein, results in resistance to caspofungin in Saccaromyces cerevisiase. Antilmicrob. Agents Chemother. (2002) 46:2462–2469.
   PubMed Web of Science ®Google Scholar
• MORA-DUARTE J, BETTS R, ROTSTEIN C et al: Comparison of caspofungin and amphotericin B for invasive candidiasis. N Engl. I Med. (2002) 347:2020–2029.
   PubMed Web of Science ®Google Scholar
• ••An important study demonstrating thatthe efficacy of caspofungin was similar to B with reduced toxicity.
   Google Scholar
• KRAUSE DS, REINHARDT J, JA et al.: Phase II, randomized, dose-ranging study evaluating the safety and efficacy of anidulafungin in invasive candidiasis and candidemia. Antimicrob. Agents Chemother. (2004) 48:2021–2024.
   PubMed Web of Science ®Google Scholar
• KRAUSE DS, SIMJEE AE, RENSBURG C et al: A randomized, double-blind trial of anidulafungin versus fluconazole for the treatment of esophageal candidiasis. Clin. Infect. Dis. (2004) (In press).
   Google Scholar
• VILLANUEVA A, GOTUZZO E, ARATHOON A et al.: A randomized double-blind study of caspofungin versus fluconazole for the treatment of esophageal candidiasis. Am. .1. Med. (2002) 113:294–299.
   Google Scholar
• LAINE L: The natural history of esophagealcandidiasis after successful treatment in patients with AIDS. Gastroenterology (1994) 107:744–746.
   PubMed Web of Science ®Google Scholar
• REX JH, PFALLER MA: Has antifungal susceptibility testing come of age? Clin. Infect. Dis. (2002) 35:982–989.
   Google Scholar
• KLEPSER ME, ERNST EJ, ERNST ME, MESSER SA, PFALLER MA: Evaluation of endpoints for antifungal susceptibility determinations with LY303366. Antimicrob. Agents Chemother. (1998) 42:1387–1391.
   PubMed Web of Science ®Google Scholar
• HERNANDEZ S, LOPEZ-RIBOT JL, NAJ VAR LK, McCARTHY DI, BOCANEGRA R, GRAYBILL JR: Caspofungin resistance in Candida albicans: correlating clinical outcome with laboratory susceptibility testing of three isogenic isolates serially obtained from a patient with progressive Candida esophagitis. Antimicrob. Agents Chemother. (2004) 48:1382–1383.
   PubMed Web of Science ®Google Scholar
• •The first documented resistance to caspofungin in a clinical isolate of. albicans.
   Google Scholar
• GROLL AH, MICKIENE D, R et al: Pharmacokinetic and pharmacodynamic modeling of anidulafungin (LY303366): reappraisal of its efficacy in neutropenic animal models of opportunistic mycoses using optimal plasma sampling. Antimicrob. Agents Chemother: (2001) 45:2845–2855.
   Google Scholar
• ••An excellent in vivo study documentingthe efficacy of anidulafungin in treating disseminated candiasis and pulmonary aspergillosis in neutropenic rabbits.
   Google Scholar
• BROWN GL, WHITE RJ, TAUBEL J: Phase I dose optimization study for V-echinocandin. Abstracts of the 40th Interscience Conference on Antimicrobial Agents and Chemotherapy Toronto, Canada (2000) Abstract 1105.
   Google Scholar
• THYE D, SHEPHERD B, WHITE RJ, VVESTON IE, HENKEL T: Anidulafungin: a Phase I study to identify the maximum tolerated dose in healthy volunteers. Abstracts of the 41st Interscience Conference on Antimicrobial Agents and Chemotherapy Chicago, USA (2001) Abstract 36.
   Google Scholar
• DOWELL JA, PU F, LEE J, M, KRAUSE D, T: A clinical mass balance study of anidulafungin showing complete fecal elimination. Abstracts of the 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy Chicago, USA (2003) Abstract A1576.
   Google Scholar
• DOWELL J, STOGNIEW M, D: Anidulafungin dosage adjustments are not required for patients with hepatic and/or renal impairment. Clin. Microbiol Infect. (2003) 9:1222.
   Google Scholar
• THYE D, KILFOIL T, WHITE RJ, LASSETER K: Anidulafungin: Pharmacokinetics in subjects with mild and moderate hepatic impairment. Abstracts of the 41st Interscience Conference on Antimicrobial Agents and Chemotherapy Chicago, USA (2001) Abstract 34.
   Google Scholar
• THYE D, KILFOIL G, KILFOIL T, HENKEL T: Anidulafungin: pharmacokinetics (PK) in subjects with severe hepatic impairment (HI). Abstracts of the 41st Interscience Conference on Antimicrobial Agents and Chemotherapy Chicago, USA (2001) Abstract A1392.
   Google Scholar
• THYE D, MARBUY T, KILFOIL T, KILFOIL G, HENKEL T: Anidulafungin: pharmacokinetics in subjects receiving hemodialysis. Abstracts of the 41st Interscience Conference on Antimicrobial Agents and Chemotherapy Chicago, USA (2001) Abstract A1390.
   Google Scholar
• THYE D, MARBUY T, KILFOIL G, KILFOIL G, HENKEL T: Anidulafungin: pharmacokinetics in subjects with renal impairment. Abstracts of the 41st Literscience Conference on Antimicrobial Agents and Chemotherapy Chicago, USA (2001) Abstract A1391.
   Google Scholar
• WHITE RJ, THYE D: Anidulafungin does not affect the metabolism of cyclosporine by human hepatic microsomes. Abstracts of the 41st Literscience Conference on Antimicrobial Agents and Chemotherapy Chicago, USA (2001) Abstract 35.
   Google Scholar
• CLEMONS K, SOBEL RA, DA: Toxicity of LY303366, an echinocandin antifungal in mice pretreated with glucocorticoids. Antimicrob. Agents Chemother: (2000) 44:378–381.
   Google Scholar
• STOGNIEW M, SENG JE, A, HENKEL T: Anidulafungin, a novel antifungal agent, produces no overt toxicity when administered to DBA/2 and BALB/c mice, with or without cortisone acetate. Vicuron (Data on file).
   Google Scholar
• ERNST ME, KLEPSER ME, WOLFE EJ, PFALLER MA: Antifungal dynamics of LY303366, an investigational echinocandin B analog, against Candida spp. Diagn. Microbiol Infect. Dis. (1996) 26:125–131.
   PubMed Web of Science ®Google Scholar
• KARLOWSKY JA, HARDING GA, ZELENITSKY SA et al.: In vitro kill curves of a new semisynthetic echinocandin LY303366, against fluconazole sensitive and resistant Candida species. Antimicrob. Agents Chemother: (1997) 41:2576–2578.
   Google Scholar
• PFALLER MA, SHEEHAN DJ, REX JH: of fungicidal activities against yeasts and molds: lessons learned from bactericidal testing and the need for standardization. Clin. Microbial. Rev (2004) 17:268–280.
   PubMed Web of Science ®Google Scholar
• ROLING EE, KLEPSER ME, A, LEWIS RE, ERNST EJ, PFALLER MA: Antifungal activities of fluconazole, caspofungin (MK0991), and anidulafungin (LY303366) alone and in combination against Candida spp. and Cryptococcus neoformansvia time-kill methods. Diagn. Microbial. Infect. Dis. (2002) 43:13–17.
   PubMed Web of Science ®Google Scholar
• PETRAITIENE R, PETRAITIS V, GROLL AH et al.: Antifungal activity of LY303366, a novel echinocandin B, in experimental disseminated candidiasis in rabbits. Antimicrob. Agents Chemother: (1999) 43:2148–2155.
   Google Scholar
• PETRAITIS V, PETRAITIENE R, GROLL A et al.: Antifungal efficacy, safety, and single dose plasma pharmacokinetics of LY3033666, a novel echinocandin B, in experimental pulmonary aspergillosis in persistently neutropenic rabbits. Antimicrob. Agents Chemother. (1998) 42:2898–2905.
   PubMed Web of Science ®Google Scholar
• •A very well done study of the in vivo activity of anidulafungin against aspergillosis.
   Google Scholar
• ZECKNER D, BUTLER T, BOYLAN CJ, BOYLL B, UN Y, RAAB P: LY303366 in a murine systemic candidiasis model. Abstracts of the 33rd Interscience Conference on Antimicrobial Agents and Chemotherapy Washington DC, USA (1993) Abstract 365.
   Google Scholar
• ZECKNER D, BUTLER T, BOYLAN C et al.: LY303366 activity against systemic aspergillosis and histoplasmosis in murine models. Abstracts of the 33rd Interscience Conference on Antimicrobial Agents and Chemotherapy Washington DC, USA (1993) Abstract 369.
   Google Scholar
• ANDES D: In vivo pharmacodynamics of antifungal drugs in treatment of candidiasis.. Agents Chemother: (2003) 47:1179–1186.
   PubMed Web of Science ®Google Scholar
• PETRAITIS V, PETRAITIENE R, GROLL AH et al.: Comparative antifungal activities and plasma pharmacokinetics of micafungin (FK463) against disseminated candidiasis and invasive pulmonary aspergillosis in persistently neutropenic rabbits. Antimicrob. Agents Chemother: (2002) 46:1857–1867.
   Google Scholar
• CHANDRASEKAR PH, CUTRIGHT J,MANAVATHU E: Efficacy of voriconazole against invasive pulmonary aspergillosis in a guinea-pig model.," Antimicrob. Chemother: (2000) 45:673–676.
   Google Scholar
• KIRKPATRICK WR, PEREA S, BJ, PATTERSON TF: Efficacy of ravuconazole (BMS-207147) in a guinea model of disseminated aspergillosis.. Chemother. (2002) 49:353–357.
   Web of Science ®Google Scholar
• PETRAITIENE R, PETRAITIS V, GROLL AH et al.: Antifungal activity and pharmacokinetics of posaconazole (5CH56592) in treatment and prevention of experimental invasive pulmonary aspergillosis: correlation with glactomannan antigenemia. Antimicrob. Agents Chemother: (2001) 45:857–869.
   Google Scholar
• KURTZ MB, HEATH IB, MARRINON J, DRIEKORN S, ONISHI J, DOUGLAS C: effects of lipopeptides against Aspergillus fumigatus correlate with activities against (1, 3)- P-D-glucan synthase. Antimicrob. Agents Chemother: (1994) 38:1480–1489.
   Google Scholar
• OAKLEY KL, MOORE CB, DW: In vitro activity of echinocandin antifungal agent LY303366 in comparison with itraconazole and amphotericin B against Aspergillusspp. Antimicrob. Agents Chemother. (1998) 42:2726–2730.
   PubMed Web of Science ®Google Scholar
• BOWMAN JC, HICKS PS, KURTZ MB et al.: The antifungal echinocandin caspofungin acetate kills growing cells of aspergillus fumigants in vitro. Antimicrob. Agents Chemother: (2002) 46:3001–3012.
   PubMed Web of Science ®Google Scholar
• ERNST EJ, KLEPSER ME, MA: Postantifungal effects of echinocandin, azole, and polyene antifungal agents against Candida albicans and Cryptococcus neoformans. Antimicrob. Agents Chemother: (2000) 44:1108–1111.
   PubMed Web of Science ®Google Scholar
• OSTROSKY-ZEICHNER L, REX JH, PAPPAS PG et al: Comparative antifungal susceptibility survey of 2,000 bloodstream isolates of Candida spp. from the United States. Antimicrob. Agents Chemother: (2003) 47:3149–3154.
   Google Scholar
• PFALLER MA, MESSER SA, S: In vitro susceptibilities of clinical yeast isolates to a new echinocandin deriative, LY303366, and other antifungal agents. Antimicrob. Agents Chemother: (1997) 41:763–766.
   Google Scholar
• ZELENITSKY S, KARLOWSKY J, HOBAN D et al.: Activity of an echinocandin, LY303366, against fluconazole susceptible and resistant Candida albicans in a multiple dose in vitro pharmacodynamic model. Abstracts of the 37th Interscience Conference on Antimicrobial Agents and Chemotherapy Toronto, Canada (1997) Abstract F72.
   Google Scholar
• ZHAENL GG, KARLOWSKY JA, ZELENITSKY S, TURIK MA, DJ: Susceptibilities of candida species isolated from the lower gastrointestinal tracts of high-risk patients to the new semisynthetic echinocandin LY303366 and other agents. Antimicrob. Agents Chemother: (1998) 42:2446–2448.
   Google Scholar
• BARTIZAL K, ODDS FC: Influences of methodological variables on susceptibility testing of caspofungin against Candida species and Aspergillus fumigatus. Antimicrob. Agents Chemother. (2003) 47:2100–2107.
   PubMed Web of Science ®Google Scholar
• KLEPSER ME, ERNST EJ, ERNST ME, PFALLER MA: Growth medium effect on the antifungal activity of LY303366. Diagn. Microbial. Infect Dis. (1997) 29:227–231.
   PubMed Web of Science ®Google Scholar
• PFALLER MA, MESSER SA, BOYKEN L al.: Further standardization of broth microdilution methodology for in vitro susceptibility testing of caspofungin against Candida species by using an international collection of more than 3000 clinical isolates. J. Clin. Microbial. (2004) 42:3117–3119.
   Google Scholar
• REX JH, PFALLER MA, WALSH TJ et al.: Antifungal susceptibility testing: practical aspects and current challenges. Clin. Microbial. Rev (2001) 14:643–658.
   PubMed Web of Science ®Google Scholar
• ODDS FC, MOTYL M, ANDRADE R et al.: Susceptibility testing with caspofungin against Candida and Aspergillus species: an interlaboratory comparison.. Agents Chemother. (2004) (In Press).
   Google Scholar
• NATIONAL COMMITTEE FOR CLINICAL LABORATORY STANDARDS: Reference method for broth dilution antifungal susceptibility testing of yeasty. approved standard (2nd edition). National Committee For Clinical Laboratory Standards, Wayne, PA, USA (2002) M27–A2.
   Google Scholar
• PFALLER MA, DIEKEMA DJ, MESSER SA, HOLLIS RJ, JONES RN: vitro activities of caspofungin compared with those of fluconazole and itraconazole against 3,959 clinical isolates of candida spp., including 157 fluconazole-resistant. Antimicrob. Agents Chemother. (2003) 47:1068–1071.
   Google Scholar
• JOHNSON EM, GOLDSTEIN BP, DAVEY KG, FRASER MA: Comparison of the in vitro activity of anidulafungin with amphotericin B, caspofungin, fluconazole, itraconazole, and voriconazole against a panel of 780 yeasts obtained from five European centres. Clin. Microbiol Infect. (2004) 10\(Suppl. 13):113.
   Google Scholar
• NATIONAL COMMITTEE FOR CLINICAL LABORATORY STANDARDS: Reference method for broth dilution antifungal susceptibility testing of filamentous fungi: approved standard M38-A. National Committee for Clinical Laboratory Standards, Wayne, PA (2002).
   Google Scholar
• WALSH TJ, GROLL A, HIEMENZ J, FLEMING R, ROILIDES E, ANAISSIE E: Infections due to emerging and uncommon medically important fungal pathogens. Clin. Microbiol Infect. Dis. (2004) 10\(Suppl. 1):48–66.
   Google Scholar
• TURNER WW, CURRENT WL: Echinocandin antifungal agents. In: Biotechnology of IndustrialAntibioties (2nd edition). Strohl WR (Ed.), Marcel Dekker, Inc., New York, USA (1997):315–334.
   Google Scholar
• PETRAITIS V, PETRAITIENE R, GROLL AH et al.: Dosage-dependent antifungal efficacy of V-echinocandin (LY303366) against experimental fluconazole-resistant oropharyngeal and esophageal candidiasis. Antimicrob. Agents Chemother. (2001) 45:471–479.
   PubMed Web of Science ®Google Scholar
• •Demonstration of dosage-dependent antifungal activity against fluconazole-resistant candidiasis.
   Google Scholar
• ROBERTS J, SCHOCK K, MARINO S, ANDRIOLE VT: Efficacacies of two new antifungal agents, the triazole ravuconazole and the echinocandin LY-303366, in an experimental model of invasive aspergillosis. Antimicrob. Agents Chemother: (2000) 44:3381–3388.
   Google Scholar
• BROWN GL, WHITE RJ, TURIK M: Phase II, randomized open label study of two intravenous dosing regimens of V-echinocandin in the treatment of esophageal candidiasis. Abstracts of the 40th Interscience Conference on Antimicrobial Agents and Chemotherapy Toronto, Canada (2000) Abstract 1104.
   Google Scholar
• ANAISSIE EJ, VARTIVARIAN SE, ABI-SAID 0 et al.: Fluconazole versus amphotericin B in the treatment of candidiasis: a matched cohort study. Am. j Med. (1996) 101:170–176.
   Google Scholar
• REX JH, BENNETT JE, SUGAR AM et al.: A randomized trial comparing fluconazole with amphotericin B for the treatment of candidemia in patients without neutropenia. N Engl. I Med. (1994) 331:1325–1330.
   PubMed Web of Science ®Google Scholar
• REX JH, PAPPAS PG, KARCHMER AW et al.: A randomized and blinded multicenter trial of high-dose fluconazole plus placebo versus fluconazole plus amphotericin B as therapy for candidemia and its consequences in non-neutropenic subjects. Clin. Infect. Dis. (2003) 36:1221–1228.
   PubMed Web of Science ®Google Scholar